Embecta (NASDAQ:EMBC) Issues FY 2025 Earnings Guidance

Embecta (NASDAQ:EMBC) updated its FY 2025 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of 2.700-2.900 for the period, compared to the consensus estimate of 2.270. The company issued revenue guidance of $1.1 billion-$1.1 billion, compared to the consensus revenue estimate of $1.1 billion.

Analyst Upgrades and Downgrades

Separately, BTIG Research upgraded Embecta from a “neutral” rating to a “buy” rating and set a $26.00 target price for the company in a report on Wednesday.

Embecta Stock Up 29.8 %

NASDAQ:EMBC opened at $18.70 on Wednesday. The firm has a market capitalization of $1.08 billion, a P/E ratio of 15.58 and a beta of 0.97. Embecta has a 52 week low of $9.93 and a 52 week high of $20.80. The company has a fifty day moving average of $14.33 and a 200 day moving average of $14.04.

Embecta Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, December 18th. Stockholders of record on Friday, December 6th will be issued a dividend of $0.15 per share. This represents a $0.60 dividend on an annualized basis and a dividend yield of 3.21%. Embecta’s dividend payout ratio is currently 50.00%.

About Embecta

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.